KYE Pharmaceuticals Inc. lero yalengeza kuti yatumiza New Drug Submission (NDS) ku Health Canada kuti iwunikenso ndikuvomereza Accrufer® (ferric maltol).
Ngati itavomerezedwa, Accrufer® ingakhale mankhwala oyamba okha achitsulo ovomerezeka ndi Health Canada ndipo chivomerezo cha malonda a Accrufer® chikuyembekezeka kukhala mkati mwa theka loyamba la 2023.
Doug Reynolds, Purezidenti wa KYE, adati: "Magulu a Shield ndi KYE adagwira ntchito molimbika kuti apange NDS yaku Canada m'miyezi ingapo ndipo ndili wokondwa kwambiri kuti ndakwaniritsa izi."
José A. Menoyo, MD, Chief Medical Officer for Shield, anawonjezera kuti: "Ndife okondwa ndi kupita patsogolo kofulumira komwe kunachitika mogwirizana ndi KYE kuyambira pomwe adasaina pangano la layisensi mu Januwale. Mabungwe onsewa awonetsa mgwirizano wabwino kwambiri ndipo amayendetsedwa kuti apangitse Accrufer® kupezeka kwa odwala ku Canada omwe ali ndi vuto lachitsulo mwachangu momwe angathere. Shield Therapeutics yadzipereka pakubweretsa Accrufer®/Feraccru® kwa odwala omwe ali ndi vuto lachitsulo padziko lonse lapansi, ndipo Canada ndi gawo lofunikira pa ntchitoyi.